Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transgenic GroupTSE:2342 -0.46%60 PS Ratio is 0.28 as of Jul. 22, 2026, which is 55% below its 10-year median of 0.62. GuruFocus rates TSE:2342 with a GF Score™ of 60/100 and a GF Value™ of 円258.12 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Transgenic Group ranks better than 97.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Transgenic Group's share price is 円218.00.
Transgenic Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円791.12. Hence, Transgenic Group's PS Ratio for today is 0.28.
Good Sign:
Transgenic Group Inc stock PS Ratio (=0.27) is close to 1-year low of 0.25.
The historical rank and industry rank for Transgenic Group's PS Ratio or its related term are showing as below:
TSE:2342'
s PS Ratio Range Over the Past 10 Years
Min: 0.19 Med: 0.62 Max: 4.93
Current: 0.28
During the past 13 years, Transgenic Group's highest PS Ratio was 4.93. The lowest was 0.19. And the median was 0.62.
TSE:2342's PS Ratio is ranked better than 97.63% of 930
companies
in the Biotechnology industry
Industry Median: 9.205
vs TSE:2342: 0.28
Transgenic Group Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Transgenic Group was 1.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.20% per year.
During the past 13 years, Transgenic Group's highest 3-Year average Revenue per Share Growth Rate was 58.30% per year. The lowest was -0.80% per year. And the median was 14.85% per year.
Back to Basics: PS Ratio
Transgenic Group (TSE:2342) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Transgenic Group PS Ratio Related Terms
Transgenic Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Transgenic Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Transgenic Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Transgenic Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Transgenic Group's Share Price of today is 円218.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transgenic Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円791.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Transgenic Group (TSE:2342) has a PS Ratio of 0.28 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Transgenic Group and its competitors. This is 55% below median its historical median of 0.62. Over the past decade, Transgenic Group's PS Ratio has ranged from 0.19 to 4.93. According to the industry distribution chart, Transgenic Group ranks #22 out of 930 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Transgenic Group's PS Ratio too high?
Transgenic Group's current PS Ratio of 0.28 is 55% below median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 4.93. The Biotechnology industry median PS Ratio is 9.21. Transgenic Group's value of 0.28 is 97% below this industry median. Based on the distribution chart, Transgenic Group ranks #22 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Transgenic Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #22 out of 930 companies for PS Ratio. This places Transgenic Group in the top 2% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.21. Transgenic Group's value of 0.28 is 97% below this benchmark. Historically, Transgenic Group's own PS Ratio has ranged from 0.19 to 4.93 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 9.21, Transgenic Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgenic Group's current PS Ratio of 0.28 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current PS Ratio is 0.28, which is 55% below median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円258.12, compared to a current price of 円218.00 — trading 15.5% below its estimated fair value. The current PS Ratio is 0.28, which is 55% below median its 10-year median of 0.62 and 97% below the Biotechnology industry median of 9.21. Transgenic Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current PS Ratio is 0.28 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円218.00 is trading 15.5% below its estimated GF Value™ of 円258.12.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
PS Ratio: 0.28 (55% below median its 10-year median of 0.62)
GF Value™: 円258.12 vs. price of 円218.00 (15.5% below fair value)
Industry Position: 97% below the Biotechnology median (#22 of 930)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
60GF Score
Get the complete analysis for TSE:2342
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
